First National Bank of Omaha Purchases New Holdings in Pfizer Inc. $PFE

First National Bank of Omaha acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the third quarter, according to its most recent disclosure with the SEC. The firm acquired 40,148 shares of the biopharmaceutical company’s stock, valued at approximately $1,023,000.

A number of other institutional investors and hedge funds have also made changes to their positions in PFE. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% during the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares in the last quarter. Grey Fox Wealth Advisors LLC purchased a new stake in shares of Pfizer in the third quarter valued at approximately $29,000. Howard Hughes Medical Institute acquired a new position in Pfizer during the second quarter worth $30,000. Darwin Wealth Management LLC purchased a new position in Pfizer in the second quarter worth $32,000. Finally, Evelyn Partners Asset Management Ltd acquired a new stake in Pfizer in the second quarter valued at $33,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 0.1%

Shares of Pfizer stock opened at $27.41 on Thursday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The business has a 50 day moving average price of $25.91 and a 200 day moving average price of $25.28. The company has a market capitalization of $155.82 billion, a P/E ratio of 20.15 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.63 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a yield of 6.3%. Pfizer’s dividend payout ratio is 126.47%.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PFE shares. TD Cowen reaffirmed a “hold” rating on shares of Pfizer in a research note on Tuesday, December 30th. Guggenheim restated a “buy” rating on shares of Pfizer in a research report on Wednesday, December 17th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a report on Wednesday, December 17th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective for the company. in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $28.00.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.